Lige Wu
Chinese Academy Of Medical Sciences And Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District
Beijing, 100021, China
Beijing, 100021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.
Journal: BMC cancer
Published: February 18, 2026
Comment on "Evaluating pathological complete response as a surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis".
Journal: International journal of surgery (London, England)
Published: December 19, 2025
Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma.
Journal: Signal transduction and targeted therapy
Published: October 18, 2025
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.
Journal: Translational lung cancer research
Published: October 09, 2025
DNAJA: emerging targets for anti-tumor therapy.
Journal: Future oncology (London, England)
Published: June 03, 2025
Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer.
Journal: Translational lung cancer research
Published: February 26, 2025
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
Journal: Journal of translational medicine
Published: April 23, 2024
Showing 1-10 of 10
Last Updated: 09/26/2026